Are peptides legal now? HHS’s 2026 peptide policy, explained
What HHS did on October 30, 2026, the six peptides it names, the conditions, and what the policy does not do.
Partly, through one path. HHS’s interim policy, published October 30, 2026, says it does not intend to take enforcement action when a state-licensed 503A pharmacy compounds BPC-157, TB-500, Epitalon, Semax, KPV or MOTS-c on a patient-specific prescription, by a listed route and under listed conditions. These peptides remain unapproved, and the policy can be revoked.
None of these six peptides is FDA-approved. HHS’s October 2026 interim policy lets state-licensed 503A pharmacies compound them on a patient-specific prescription under listed conditions.
REMEVi does not currently offer BPC-157, TB-500, Epitalon, Semax, KPV or MOTS-c.
What HHS did, and when
On October 28, 2026, HHS filed a notice announcing HHS’s interim enforcement-discretion policy for 503A compounding (Federal Register, October 30, 2026). The notice of availability, signed by HHS Secretary Robert F. Kennedy, Jr., appears at 91 FR 68526 (FR Doc. 2026-22192, Docket HHS-OASH-2026-0496).
In it, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, a federal facility or a licensed practitioner that compounds a drug product with a peptide bulk drug substance found in the policy’s Appendix A. The policy applies while the list of bulk substances allowed in 503A compounding, the 503A bulks list, is developed through rulemaking.
The Federal Register notice · The policy document itself (PDF, hosted by HHS)
The policy PDF is the HHS document the notice points to; it could not be opened when we checked on November 2, 2026, so the routes and conditions on this page come from the notice and the legal and trade coverage listed under Sources.
The six peptides and the routes HHS lists
| Peptide | Substance named | Routes listed | REMEVi |
|---|---|---|---|
| BPC-157 | BPC-157 acetate | subcutaneous, intramuscular, oral and topical | Not currently offered |
| TB-500 | TB-500 acetate | subcutaneous or intramuscular injection | Not currently offered |
| Epitalon | Epitalon acetate | injection, in intermittent courses | Not currently offered |
| Semax | Semax free base | intranasal | Not currently offered |
| KPV | KPV acetate | topical and oral | Not currently offered |
| MOTS-c | MOTS-c acetate | subcutaneous or intramuscular injection | Not currently offered |
A route that is not listed is outside the policy. Epitalon’s listing says “intermittent courses” without defining them.
The conditions a compounded product must meet
Legal coverage of the policy lists ten conditions, all of which must be met:
- The peptide appears in the policy’s appendix.
- It has the identity and the limited route of administration stated in the appendix.
- The bulk substance comes from an FDA-registered facility with a valid certificate of analysis.
- The original bulk manufacturer is FDA-registered and compliant with current good manufacturing practice (CGMP).
- Serious adverse events are reported to FDA’s MedWatch program.
- The label reads “This is a compounded drug product. Not for resale.”
- The product contains a single active ingredient; blends are not covered.
- For oral products, the compounder keeps documentation that the formulation is adequately bioavailable in humans.
- No device other than an FDA 510(k)-cleared syringe is packaged with or contains the drug.
- The product is compounded in line with all other applicable provisions of the Federal Food, Drug, and Cosmetic Act.
HHS has described the policy as requiring patient-specific prescriptions, traceable ingredients, quality testing and safety reporting.
What the policy is not
- It is not FDA approval. Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness or quality before they are marketed.
- It is not a finding that these peptides are safe or effective.
- It does not add the six to the 503A bulks list. FDA’s future rulemaking may propose adding some or all of them, based on the evidence.
- It is interim and non-binding: it “does not establish any rights for any person,” and HHS may revisit it if a safety signal or product quality issue arises.
- It is open for comment. The notice calls it a draft, with written comments accepted for two weeks after publication (through November 13, 2026) on Docket HHS-OASH-2026-0496. No end date was given.
- It covers 503A compounding. 503B outsourcing facilities are not covered.
- It does not cover products sold as research chemicals or as dietary supplements.
What it means if you buy “research” peptides online
Vials sold online with a “for research use only” label are not compounded prescriptions. They are not prepared by a licensed pharmacy for a named patient, and they fall outside HHS’s policy.
On August 24, 2026, FDA sent warning letters to five online peptide vendors. According to Holland & Knight, the letters said research-use labels did not outweigh evidence that the products were intended for human use, pointing to bacteriostatic water sold for mixing and dosing calculators offered alongside them.
The policy’s path runs through a licensed prescriber and a state-licensed 503A pharmacy, with sourcing, labeling and safety-reporting conditions that a research-labeled vial does not meet.
How a legal prescription path works
- A licensed prescriber evaluates you and decides whether one of the six is appropriate for you.
- The prescriber writes a patient-specific prescription for a single peptide, by a route the policy lists.
- A state-licensed 503A pharmacy compounds it from a bulk substance made by an FDA-registered, CGMP-compliant manufacturer and supplied with a valid certificate of analysis.
- The product is dispensed with the label “This is a compounded drug product. Not for resale.” and with no device other than an FDA 510(k)-cleared syringe.
- Serious adverse events are reported to FDA MedWatch. Tell your prescriber about any reaction.
Background: how the policy came about
- 2023: FDA placed BPC-157 and other peptides in Category 2 of its interim bulks policy, a designation for substances it believed raised significant safety risks.
- April 15, 2026: FDA announced it would remove 12 peptides from Category 2, without making any of them eligible for compounding.
- June 29, 2026: FDA staff briefing documents recommended against adding the peptides under review to the 503A bulks list.
- July 23–24, 2026: FDA’s Pharmacy Compounding Advisory Committee voted to recommend the six peptides and voted against a seventh, emideltide. The votes were advisory.
- August 24, 2026: FDA sent five warning letters to online peptide vendors.
- October 28–30, 2026: HHS filed and published the interim enforcement-discretion policy.
Which of the six REMEVi offers today
None. REMEVi does not currently offer BPC-157, TB-500, Epitalon, Semax, KPV or MOTS-c, and nothing on this page is an offer of them. REMEVi prescribes NAD+, sermorelin and GLP-1 medications through the same model the policy describes: a licensed provider’s prescription and a licensed compounding pharmacy.
Is BPC-157 legal now?
BPC-157 is not FDA-approved. Since HHS’s interim policy, published October 30, 2026, HHS does not intend to take enforcement action when a state-licensed 503A pharmacy compounds BPC-157 on a patient-specific prescription, by subcutaneous, intramuscular, oral or topical route, under listed conditions. Vials labeled for research use fall outside the policy.
Which peptides can be compounded in 2026?
HHS’s interim policy names six: BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-c, each by specific routes. A state-licensed 503A pharmacy may compound them on a patient-specific prescription under ten conditions, including a single active ingredient and a registered, certified bulk source. The policy is interim and can be revisited at any time.
Are peptides FDA-approved?
The six peptides in HHS’s 2026 policy are not FDA-approved, and the policy does not change that. Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness or quality before they are marketed. The policy is a decision not to take enforcement action under conditions, not an approval or a safety finding.
Are “research” peptides sold online covered by the policy?
Products sold online as “research use only” are not compounded prescriptions and are outside HHS’s policy. FDA sent warning letters to five online peptide vendors on August 24, 2026, saying research labels did not outweigh evidence the products were meant for people. The policy’s path is a licensed prescriber and a state-licensed 503A pharmacy.
More questions
Does the policy cover peptide blends?
No. One of the conditions is a single active ingredient per compounded product, so blends of two or more peptides are not covered.
Does the policy cover outsourcing facilities?
No. It covers 503A compounding, by state-licensed pharmacies, federal facilities and licensed practitioners. 503B outsourcing facilities are not covered.
How long does the policy last?
No end date was given. It applies while FDA develops the 503A bulks list through rulemaking, and HHS may revisit it if a safety signal or product quality issue arises.
Sources
- HHS, Office of the Secretary — Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, notice of availability, 91 FR 68526 (October 30, 2026), FR Doc. 2026-22192 (read November 2, 2026)
- Holtz, Beaver & Rosen (Foley & Lardner), National Law Review, October 30, 2026 — HHS announces limited enforcement discretion for compounding of six peptides (read November 2, 2026)
- Bigica, Nutritional Outlook, November 2, 2026 — What the interim compounding pathway for peptides could mean for supplement brands (read November 2, 2026)
- Steinzor, AJMC, October 29, 2026 — 5 things to know about HHS’s interim peptide compounding policy (read November 2, 2026)
- NCPA qAM, October 29, 2026 — FDA grants enforcement discretion to compounding six peptides (read November 2, 2026)
- Crossan & Watkins (Holland & Knight), October 16, 2026 — Peptides at a crossroads: what wellness providers need to know about HHS and FDA actions (read November 2, 2026)
- FDA — Understanding the risks of compounded drugs (read November 2, 2026)
Medically reviewed by Linda West-Conforti, RN · CA RN #389453 ·